@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_head { this: np:hasAssertion dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_assertion; np:hasProvenance dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_provenance; np:hasPublicationInfo dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_publicationInfo; a np:Nanopublication . dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_assertion a np:Assertion . dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_provenance a np:Provenance . dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_publicationInfo a np:PublicationInfo . } dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_assertion { miriam-gene:7157 a ncit:C16612 . lld:C0029925 a ncit:C7057 . dgn-gda:DGNe18b7cd16e5b5e51323db7021acb4622 sio:SIO_000628 miriam-gene:7157, lld:C0029925; a sio:SIO_001121 . } dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_provenance { dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_assertion dcterms:description "[We have found that: (1) the heterozygous arginine/proline allelotype is more common in probands with borderline cancers than in probands with invasive cancers (P = .0001) or healthy controls (P = .005); (2) despite a survival advantage (P = .006), probands homozygous for the arginine allele developed ovarian cancer at an earlier age (P = .01); (3) the frequency of tumor p53 mutations was independent of the germline p53 allelotype, but (4) when a loss of heterozygosity occurred in probands with invasive disease, the proline allele was lost preferentially (P = .002), and (5) any tumor which retained a proline allele was more prone to mutation (P = .04) than a tumor without a proline allele.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:9253509; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP161390.RApw981vqrI-_zUExkrhQ4FojkjsYsZbR2Wxc-d09ZBUE130_publicationInfo { this: dcterms:created "2014-10-02T12:33:27+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }